COMPARISON OF CONVENTIONAL AND HIGH-SENSITIVITY TROPONIN IN PATIENTS PRESENTING TO THE EMERGENCY DEPARTMENT WITH CHEST PAIN: A COLLABORATIVE META-ANALYSIS  by Lipinski, Michael et al.
A16
JACC April 1, 2014
Volume 63, Issue 12
Acute Coronary Syndromes
Comparison of Conventional and HigH-sensitivity troponin in patients presenting to tHe 
emergenCy department witH CHest pain: a Collaborative meta-analysis
Oral Contributions
Room 150 B
Saturday, March 29, 2014, 8:15 a.m.-8:30 a.m.
Session Title: Novel Strategies for Diagnosis and Risk Assessment in ACS
Abstract Category: 1. Acute Coronary Syndromes: Clinical
Presentation Number: 900-04
Authors: Michael Lipinski, Nevin Baker, Ricardo Escarcega Alarcon, Rebecca Torguson, Stephen Epstein, Sally Aldous, Michael Christ, Paul 
Collinson, Johannes Mair, Kenji Inoue, Ulrich Lotze, Mustapha Sebbane, Jean-Paul Cristol, Yonathan Freund, Camille Chenevier-Gobeaux, 
Christophe Meune, Kai Eggers, Radoslaw Pracon, Donald Schreiber, Alan Wu, Jordi Ordoñez-Llanos, Allan Jaffe, Raphael Twerenbold, Christian 
Mueller, Ron Waksman, Medstar Washington Hospital Center, Washington, DC, USA, Meta-Analysis Collaborative Group
background:  Multiple studies have evaluated the diagnostic and prognostic accuracy of conventional and high sensitivity troponin (hs-cTn) 
with varying results. The standard assay was usually used to define acute myocardial infarction (AMI). We performed a collaborative meta-analysis 
comparing conventional and hs-cTn for diagnosis of AMI and assessment of prognosis in patients with chest pain.
methods: MEDLINE/PubMed, Cochrane CENTRAL, and EMBASE were searched for studies assessing both conventional and hs-cTn in patients with 
chest pain. Study authors were contacted and many provided previously unpublished data. Random-effects methods were used to compare the data 
for conventional and hs-cTn.
results: From the 17 included studies, there were 8,644 patients. Mean age was 62 years, 63% were male, and 20.7% were diagnosed with AMI. 
All but 5 studies utilized the 99th percentile cut-point to define AMI for conventional cTn. Compared with admission conventional Tn, hs-cTn had 
significantly greater sensitivity (0.88 vs 0.74, p<0.001) and negative predictive value (NPV)(0.96 vs 0.93, p<0.001) while specificity (0.82 vs 0.94, 
p<0.001) and positive predictive value (PPV)(0.56 vs 0.76, p<0.001) were significantly reduced. Based on summary ROC curves, diagnostic accuracy 
was not significantly different for AMI between conventional and hs-cTn on admission (0.90 [95% CI 0.85-0.95] vs 0.92 [95% CI 0.90-0.94]). In a 
sub-analysis of 6 studies that alternatively defined AMI based on hs-cTn, conventional cTn had a further reduction in sensitivity and NPV. Additionally, 
when compared with negative admission biomarkers, an elevated hs-cTn (odds ratio 4.9 [95% CI 2.8-8.7]) and an elevated conventional cTn (odds 
ratio 4.0 [95% CI 2.6-6.1]) were both associated with increased all-cause mortality during follow-up (mean 12 ± 9 months).
Conclusions: Admission hs-cTn has significantly greater sensitivity and NPV compared with conventional cTn at the cost of specificity and PPV for 
the diagnosis of AMI. Thus, hs-cTn may enable earlier detection of AMI and help early rule out of AMI in patients with chest pain.
